Loading…

Cardioprotective Effect of Aprotinin on Myocardial Ischemia/Reperfusion Injury During Cardiopulmonary Bypass

Background Aprotinin is a serine protease inhibitor used extensively in cardiac operations to reduce postoperative bleeding. It also has cardioprotective effects in ischemia/reperfusion injury. In this study, the effects of aprotinin on the release of cardiac markers were evaluated in patients who h...

Full description

Saved in:
Bibliographic Details
Published in:Circulation Journal 2006, Vol.70(11), pp.1432-1436
Main Authors: Karaca, Pelin, Konuralp, Cüneyt, Enc, Yavuz, Süzer, Asuman, Sokullu, Onur, Ayoglu, Umut, Cicek, Sertac
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c582t-9833a45f5747557758924614417155a30f8c06595ea331219c0601c595abf9663
cites cdi_FETCH-LOGICAL-c582t-9833a45f5747557758924614417155a30f8c06595ea331219c0601c595abf9663
container_end_page 1436
container_issue 11
container_start_page 1432
container_title Circulation Journal
container_volume 70
creator Karaca, Pelin
Konuralp, Cüneyt
Enc, Yavuz
Süzer, Asuman
Sokullu, Onur
Ayoglu, Umut
Cicek, Sertac
description Background Aprotinin is a serine protease inhibitor used extensively in cardiac operations to reduce postoperative bleeding. It also has cardioprotective effects in ischemia/reperfusion injury. In this study, the effects of aprotinin on the release of cardiac markers were evaluated in patients who had good ventricular function and were undergoing coronary artery bypass grafting with cardiopulmonary bypass (CPB). Methods and Results Eighty male patients with an ejection fraction ≥40%, were randomized into either an aprotinin (Group-I; n=40) or control (Group-II; n=40) group. Patients in the aprotinin group received the full Hammersmith doses of aprotinin (2×106 KIU pre-CPB, 2×106 KIU at pump prime, 500,000 KIU/h during CPB), whereas the patients in the control group received only saline solutions. Cardiac troponin-I (cTnI) levels were measured before surgery, immediately after surgery, and at postoperative 6th, 12th, 24th h and 5th day. Creatine kinase (CK)-MB measurements were performed at the same time except for the postoperative 5th day. Cardiac index (CI), mixed venous oxygen saturation and lactate dehydrogenase (LDH) measurements were also performed. Conclusion Although all patients were in reasonable condition, less myocardial enzyme leakage occurred on the aprotinin group, suggesting that aprotinin has a protective effect on the myocardium beyond that achieved with blood cardioplegia and systemic hypothermia. Because of aprotinin's effects on multiple targets of metabolism, its protective value might increase in more complicated cases. (Circ J 2006; 70: 1432 - 1436)
doi_str_mv 10.1253/circj.70.1432
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68987661</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68987661</sourcerecordid><originalsourceid>FETCH-LOGICAL-c582t-9833a45f5747557758924614417155a30f8c06595ea331219c0601c595abf9663</originalsourceid><addsrcrecordid>eNpNkM9PwjAUxxujEUSPXs1O3gbt-ms7IqCSYEyMnpdSWuiyrdhuJvz3drCIl_Z93_vkm_e-ANwjOEYJxRNpnCzGPCiCkwswRJjwmKQJvDzWLM5SggfgxvsCwiSDNLsGA8QhSzLGhqCcCbcxdu9so2RjflS00DpUkdXRtOua2tSRraO3g5UdKspo6eVOVUZMPtReOd16E-bLumjdIZq3ztTbqHdty8rWIrSfDnvh_S240qL06q7_R-DrefE5e41X7y_L2XQVS5omTdgYY0GoppxwSjmnaZYQhghBHFEqMNSphIxmVAmMUYKyoCCSoSHWOlyFR-Dx5BsO-G6Vb_LKeKnKUtTKtj5naZZyxlAA4xMonfXeKZ3vnanCwjmCeRdvfow350GFeAP_0Bu360ptznSfZwDmJ6DwjdiqP0C4xshS_bND_dv5nsc74XJV418r4o8I</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68987661</pqid></control><display><type>article</type><title>Cardioprotective Effect of Aprotinin on Myocardial Ischemia/Reperfusion Injury During Cardiopulmonary Bypass</title><source>Freely Accessible Medical Journals</source><creator>Karaca, Pelin ; Konuralp, Cüneyt ; Enc, Yavuz ; Süzer, Asuman ; Sokullu, Onur ; Ayoglu, Umut ; Cicek, Sertac</creator><creatorcontrib>Karaca, Pelin ; Konuralp, Cüneyt ; Enc, Yavuz ; Süzer, Asuman ; Sokullu, Onur ; Ayoglu, Umut ; Cicek, Sertac</creatorcontrib><description>Background Aprotinin is a serine protease inhibitor used extensively in cardiac operations to reduce postoperative bleeding. It also has cardioprotective effects in ischemia/reperfusion injury. In this study, the effects of aprotinin on the release of cardiac markers were evaluated in patients who had good ventricular function and were undergoing coronary artery bypass grafting with cardiopulmonary bypass (CPB). Methods and Results Eighty male patients with an ejection fraction ≥40%, were randomized into either an aprotinin (Group-I; n=40) or control (Group-II; n=40) group. Patients in the aprotinin group received the full Hammersmith doses of aprotinin (2×106 KIU pre-CPB, 2×106 KIU at pump prime, 500,000 KIU/h during CPB), whereas the patients in the control group received only saline solutions. Cardiac troponin-I (cTnI) levels were measured before surgery, immediately after surgery, and at postoperative 6th, 12th, 24th h and 5th day. Creatine kinase (CK)-MB measurements were performed at the same time except for the postoperative 5th day. Cardiac index (CI), mixed venous oxygen saturation and lactate dehydrogenase (LDH) measurements were also performed. Conclusion Although all patients were in reasonable condition, less myocardial enzyme leakage occurred on the aprotinin group, suggesting that aprotinin has a protective effect on the myocardium beyond that achieved with blood cardioplegia and systemic hypothermia. Because of aprotinin's effects on multiple targets of metabolism, its protective value might increase in more complicated cases. (Circ J 2006; 70: 1432 - 1436)</description><identifier>ISSN: 1346-9843</identifier><identifier>EISSN: 1347-4820</identifier><identifier>DOI: 10.1253/circj.70.1432</identifier><identifier>PMID: 17062966</identifier><language>eng</language><publisher>Japan: The Japanese Circulation Society</publisher><subject>Adult ; Aged ; Aprotinin ; Aprotinin - pharmacology ; Aprotinin - therapeutic use ; Cardiopulmonary bypass ; Cardiopulmonary Bypass - methods ; Coronary Artery Disease - surgery ; Creatine Kinase, MB Form - blood ; Double-Blind Method ; Heart - drug effects ; Heart - physiopathology ; Heart Arrest, Induced - adverse effects ; Humans ; Hypothermia - physiopathology ; Ischemia ; L-Lactate Dehydrogenase - blood ; Male ; Middle Aged ; Prospective Studies ; Reperfusion injury ; Reperfusion Injury - blood ; Reperfusion Injury - drug therapy ; Reperfusion Injury - physiopathology ; Reperfusion Injury - prevention &amp; control ; Serine Proteinase Inhibitors - pharmacology ; Serine Proteinase Inhibitors - therapeutic use ; Troponin ; Troponin T - blood</subject><ispartof>Circulation Journal, 2006, Vol.70(11), pp.1432-1436</ispartof><rights>2006 THE JAPANESE CIRCULATION SOCIETY</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c582t-9833a45f5747557758924614417155a30f8c06595ea331219c0601c595abf9663</citedby><cites>FETCH-LOGICAL-c582t-9833a45f5747557758924614417155a30f8c06595ea331219c0601c595abf9663</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17062966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karaca, Pelin</creatorcontrib><creatorcontrib>Konuralp, Cüneyt</creatorcontrib><creatorcontrib>Enc, Yavuz</creatorcontrib><creatorcontrib>Süzer, Asuman</creatorcontrib><creatorcontrib>Sokullu, Onur</creatorcontrib><creatorcontrib>Ayoglu, Umut</creatorcontrib><creatorcontrib>Cicek, Sertac</creatorcontrib><title>Cardioprotective Effect of Aprotinin on Myocardial Ischemia/Reperfusion Injury During Cardiopulmonary Bypass</title><title>Circulation Journal</title><addtitle>Circ J</addtitle><description>Background Aprotinin is a serine protease inhibitor used extensively in cardiac operations to reduce postoperative bleeding. It also has cardioprotective effects in ischemia/reperfusion injury. In this study, the effects of aprotinin on the release of cardiac markers were evaluated in patients who had good ventricular function and were undergoing coronary artery bypass grafting with cardiopulmonary bypass (CPB). Methods and Results Eighty male patients with an ejection fraction ≥40%, were randomized into either an aprotinin (Group-I; n=40) or control (Group-II; n=40) group. Patients in the aprotinin group received the full Hammersmith doses of aprotinin (2×106 KIU pre-CPB, 2×106 KIU at pump prime, 500,000 KIU/h during CPB), whereas the patients in the control group received only saline solutions. Cardiac troponin-I (cTnI) levels were measured before surgery, immediately after surgery, and at postoperative 6th, 12th, 24th h and 5th day. Creatine kinase (CK)-MB measurements were performed at the same time except for the postoperative 5th day. Cardiac index (CI), mixed venous oxygen saturation and lactate dehydrogenase (LDH) measurements were also performed. Conclusion Although all patients were in reasonable condition, less myocardial enzyme leakage occurred on the aprotinin group, suggesting that aprotinin has a protective effect on the myocardium beyond that achieved with blood cardioplegia and systemic hypothermia. Because of aprotinin's effects on multiple targets of metabolism, its protective value might increase in more complicated cases. (Circ J 2006; 70: 1432 - 1436)</description><subject>Adult</subject><subject>Aged</subject><subject>Aprotinin</subject><subject>Aprotinin - pharmacology</subject><subject>Aprotinin - therapeutic use</subject><subject>Cardiopulmonary bypass</subject><subject>Cardiopulmonary Bypass - methods</subject><subject>Coronary Artery Disease - surgery</subject><subject>Creatine Kinase, MB Form - blood</subject><subject>Double-Blind Method</subject><subject>Heart - drug effects</subject><subject>Heart - physiopathology</subject><subject>Heart Arrest, Induced - adverse effects</subject><subject>Humans</subject><subject>Hypothermia - physiopathology</subject><subject>Ischemia</subject><subject>L-Lactate Dehydrogenase - blood</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Prospective Studies</subject><subject>Reperfusion injury</subject><subject>Reperfusion Injury - blood</subject><subject>Reperfusion Injury - drug therapy</subject><subject>Reperfusion Injury - physiopathology</subject><subject>Reperfusion Injury - prevention &amp; control</subject><subject>Serine Proteinase Inhibitors - pharmacology</subject><subject>Serine Proteinase Inhibitors - therapeutic use</subject><subject>Troponin</subject><subject>Troponin T - blood</subject><issn>1346-9843</issn><issn>1347-4820</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNpNkM9PwjAUxxujEUSPXs1O3gbt-ms7IqCSYEyMnpdSWuiyrdhuJvz3drCIl_Z93_vkm_e-ANwjOEYJxRNpnCzGPCiCkwswRJjwmKQJvDzWLM5SggfgxvsCwiSDNLsGA8QhSzLGhqCcCbcxdu9so2RjflS00DpUkdXRtOua2tSRraO3g5UdKspo6eVOVUZMPtReOd16E-bLumjdIZq3ztTbqHdty8rWIrSfDnvh_S240qL06q7_R-DrefE5e41X7y_L2XQVS5omTdgYY0GoppxwSjmnaZYQhghBHFEqMNSphIxmVAmMUYKyoCCSoSHWOlyFR-Dx5BsO-G6Vb_LKeKnKUtTKtj5naZZyxlAA4xMonfXeKZ3vnanCwjmCeRdvfow350GFeAP_0Bu360ptznSfZwDmJ6DwjdiqP0C4xshS_bND_dv5nsc74XJV418r4o8I</recordid><startdate>2006</startdate><enddate>2006</enddate><creator>Karaca, Pelin</creator><creator>Konuralp, Cüneyt</creator><creator>Enc, Yavuz</creator><creator>Süzer, Asuman</creator><creator>Sokullu, Onur</creator><creator>Ayoglu, Umut</creator><creator>Cicek, Sertac</creator><general>The Japanese Circulation Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2006</creationdate><title>Cardioprotective Effect of Aprotinin on Myocardial Ischemia/Reperfusion Injury During Cardiopulmonary Bypass</title><author>Karaca, Pelin ; Konuralp, Cüneyt ; Enc, Yavuz ; Süzer, Asuman ; Sokullu, Onur ; Ayoglu, Umut ; Cicek, Sertac</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c582t-9833a45f5747557758924614417155a30f8c06595ea331219c0601c595abf9663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aprotinin</topic><topic>Aprotinin - pharmacology</topic><topic>Aprotinin - therapeutic use</topic><topic>Cardiopulmonary bypass</topic><topic>Cardiopulmonary Bypass - methods</topic><topic>Coronary Artery Disease - surgery</topic><topic>Creatine Kinase, MB Form - blood</topic><topic>Double-Blind Method</topic><topic>Heart - drug effects</topic><topic>Heart - physiopathology</topic><topic>Heart Arrest, Induced - adverse effects</topic><topic>Humans</topic><topic>Hypothermia - physiopathology</topic><topic>Ischemia</topic><topic>L-Lactate Dehydrogenase - blood</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Prospective Studies</topic><topic>Reperfusion injury</topic><topic>Reperfusion Injury - blood</topic><topic>Reperfusion Injury - drug therapy</topic><topic>Reperfusion Injury - physiopathology</topic><topic>Reperfusion Injury - prevention &amp; control</topic><topic>Serine Proteinase Inhibitors - pharmacology</topic><topic>Serine Proteinase Inhibitors - therapeutic use</topic><topic>Troponin</topic><topic>Troponin T - blood</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karaca, Pelin</creatorcontrib><creatorcontrib>Konuralp, Cüneyt</creatorcontrib><creatorcontrib>Enc, Yavuz</creatorcontrib><creatorcontrib>Süzer, Asuman</creatorcontrib><creatorcontrib>Sokullu, Onur</creatorcontrib><creatorcontrib>Ayoglu, Umut</creatorcontrib><creatorcontrib>Cicek, Sertac</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation Journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karaca, Pelin</au><au>Konuralp, Cüneyt</au><au>Enc, Yavuz</au><au>Süzer, Asuman</au><au>Sokullu, Onur</au><au>Ayoglu, Umut</au><au>Cicek, Sertac</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardioprotective Effect of Aprotinin on Myocardial Ischemia/Reperfusion Injury During Cardiopulmonary Bypass</atitle><jtitle>Circulation Journal</jtitle><addtitle>Circ J</addtitle><date>2006</date><risdate>2006</risdate><volume>70</volume><issue>11</issue><spage>1432</spage><epage>1436</epage><pages>1432-1436</pages><issn>1346-9843</issn><eissn>1347-4820</eissn><abstract>Background Aprotinin is a serine protease inhibitor used extensively in cardiac operations to reduce postoperative bleeding. It also has cardioprotective effects in ischemia/reperfusion injury. In this study, the effects of aprotinin on the release of cardiac markers were evaluated in patients who had good ventricular function and were undergoing coronary artery bypass grafting with cardiopulmonary bypass (CPB). Methods and Results Eighty male patients with an ejection fraction ≥40%, were randomized into either an aprotinin (Group-I; n=40) or control (Group-II; n=40) group. Patients in the aprotinin group received the full Hammersmith doses of aprotinin (2×106 KIU pre-CPB, 2×106 KIU at pump prime, 500,000 KIU/h during CPB), whereas the patients in the control group received only saline solutions. Cardiac troponin-I (cTnI) levels were measured before surgery, immediately after surgery, and at postoperative 6th, 12th, 24th h and 5th day. Creatine kinase (CK)-MB measurements were performed at the same time except for the postoperative 5th day. Cardiac index (CI), mixed venous oxygen saturation and lactate dehydrogenase (LDH) measurements were also performed. Conclusion Although all patients were in reasonable condition, less myocardial enzyme leakage occurred on the aprotinin group, suggesting that aprotinin has a protective effect on the myocardium beyond that achieved with blood cardioplegia and systemic hypothermia. Because of aprotinin's effects on multiple targets of metabolism, its protective value might increase in more complicated cases. (Circ J 2006; 70: 1432 - 1436)</abstract><cop>Japan</cop><pub>The Japanese Circulation Society</pub><pmid>17062966</pmid><doi>10.1253/circj.70.1432</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1346-9843
ispartof Circulation Journal, 2006, Vol.70(11), pp.1432-1436
issn 1346-9843
1347-4820
language eng
recordid cdi_proquest_miscellaneous_68987661
source Freely Accessible Medical Journals
subjects Adult
Aged
Aprotinin
Aprotinin - pharmacology
Aprotinin - therapeutic use
Cardiopulmonary bypass
Cardiopulmonary Bypass - methods
Coronary Artery Disease - surgery
Creatine Kinase, MB Form - blood
Double-Blind Method
Heart - drug effects
Heart - physiopathology
Heart Arrest, Induced - adverse effects
Humans
Hypothermia - physiopathology
Ischemia
L-Lactate Dehydrogenase - blood
Male
Middle Aged
Prospective Studies
Reperfusion injury
Reperfusion Injury - blood
Reperfusion Injury - drug therapy
Reperfusion Injury - physiopathology
Reperfusion Injury - prevention & control
Serine Proteinase Inhibitors - pharmacology
Serine Proteinase Inhibitors - therapeutic use
Troponin
Troponin T - blood
title Cardioprotective Effect of Aprotinin on Myocardial Ischemia/Reperfusion Injury During Cardiopulmonary Bypass
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T11%3A25%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardioprotective%20Effect%20of%20Aprotinin%20on%20Myocardial%20Ischemia/Reperfusion%20Injury%20During%20Cardiopulmonary%20Bypass&rft.jtitle=Circulation%20Journal&rft.au=Karaca,%20Pelin&rft.date=2006&rft.volume=70&rft.issue=11&rft.spage=1432&rft.epage=1436&rft.pages=1432-1436&rft.issn=1346-9843&rft.eissn=1347-4820&rft_id=info:doi/10.1253/circj.70.1432&rft_dat=%3Cproquest_cross%3E68987661%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c582t-9833a45f5747557758924614417155a30f8c06595ea331219c0601c595abf9663%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=68987661&rft_id=info:pmid/17062966&rfr_iscdi=true